Patients Physicians Prescription Transportation 
Pharmaceutical Technology
JUNE 14, 2023
Ipsen has received US Food and Drug Administration (FDA) approval for Bylvay (odevixibat) to treat patients aged 12 months and above with cholestatic pruritus caused by Alagille syndrome (ALGS). More than 90% of patients who received treatment with odevixibat were pruritus responders.
PM360
JULY 13, 2023
If one of those conditions is type 2 diabetes, that person may be taking seven prescription medications, 1 managing two or more additional chronic conditions, 2 and paying $13,000 per year on healthcare. senior adults (aged 65+) 7 taking five or more prescription medications. 3 They are also 2.6 In the U.S., 5 This links to 22% of U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clarify Health
JANUARY 26, 2022
It is a real-world evidence-based software product that empowers life sciences companies to improve the recruitment of diverse and underrepresented patient populations. These data are linked to government and commercial claims, clinical, prescription and dispensing data, covering over 300 million patient lives.
World of DTC Marketing
APRIL 14, 2021
8 spot ahead of industries such as retail, transportation, and media, and entertainment. BMS believes they price our medicines based on the value they deliver,” but physicians say the price is too high. The best prospects are drugs targeted at patients who are high-value and who will use the drugs long term.
PM360
JULY 13, 2023
PM360 asked experts in helping patients stay on their prescribed therapies about where the industry could make the biggest improvements and how to better detect potential barriers. How can the industry better monitor and detect potential barriers to adherence for individual patients? How can they improve?
Clarify Health
NOVEMBER 21, 2022
Earlier this year, Clarify Health began offering a new service ( Clarify Trials ) whereby companies could receive a list of the most-ideal sites for studies tied to the characteristics of patients they hope to enroll. It essentially offered an assessment of risk that would initially be available to care-planning clinicians.
Clarify Health
NOVEMBER 21, 2022
Earlier this year, Clarify Health began offering a new service ( Clarify Trials ) whereby companies could receive a list of the most-ideal sites for studies tied to the characteristics of patients they hope to enroll. It essentially offered an assessment of risk that would initially be available to care-planning clinicians.
Expert insights. Personalized for you.
52 
Let's personalize your content